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Abstract
Background: The objectives of this study are to determine the effects of regularly scheduled administration of
paracetamol (acetaminophen) on quality of life (QoL), discomfort, pain and neuropsychiatric symptoms of persons
with dementia living in long-term care facilities (LTCFs).
Methods: A multicentre randomised double-blind placebo-controlled crossover trial for 13 weeks (January 2018 to
June 2019) in 17 LTCFs across the west of the Netherlands. Inclusion criteria were age ≥ 65 years, (advanced)
dementia and a moderate to low QoL, independent of the presence of pain (QUALIDEM ≤ 70). Exclusion criteria
were the use of regular pain treatment, allergies to the study medication, severe liver disease, use of > 4 units of
alcohol/day, weight < 50 kg and/or concomitant use of flucloxacillin. Participants received study medication
(paracetamol/placebo) in two periods of 6 weeks each (1 week in between as a wash-out period). Randomisation
decided in which order participants received paracetamol and placebo. Primary outcomes included QoL
(QUALIDEM) and discomfort (DS-DAT), secondary outcomes included pain (MOBID-2) and neuropsychiatric
symptoms (NPI-NH).
Results: Ninety-five LTCF residents (mean age 83.9 years [SD 7.6], 57.9% females) were included. Repeated linear
mixed models showed no difference in mean differences of QUALIDEM (paracetamol +1.3 [95% CI -1.0–3.5],
placebo +1.5 [95% CI -0.7–3.8]), DS-DAT (paracetamol -0.1 [95% CI -1.4–1.2], placebo 0.6 [95 CI -0.7–1.8]), MOBID-2
(paracetamol 0.0 [95% CI -0.5–0.5], placebo -0.2 [95% CI -0.7–0.3]) and NPI-NH (paracetamol +1.5 [95% CI -2.3–5.4],
placebo -2.1 [95% CI -6.0–1.7]) in favour of either paracetamol or placebo.
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Conclusions: Compared to placebo, paracetamol showed no positive effect on QoL, discomfort, pain and
neuropsychiatric symptoms in persons with advanced dementia with low QoL. It is important to find out more
specifically which individual persons with advanced dementia could benefit from pain treatment with paracetamol,
and for clinicians to acknowledge that a good assessment, monitoring and multidomain approach is vital for
improving QoL in this vulnerable group.
Trial registration: Netherlands Trial Register NTR6766. Trial registration date: 20 October 2017
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Background
The expected increase in the number of persons with de-
mentia in future decades [1] emphasises that caregivers
need to be able to cope with the difficulties they experience
daily in order to maintain optimal quality of life (QoL) in
this population. The focus on QoL has become more and
more pronounced in recent decades, but as the persons
with dementia are mostly unable to adequately indicate
how they experience their QoL, the intricate task of safe-
guarding it for them falls to the people around them [2]. In
a long-term care facility (LTCF), there are even more (pro-
fessional) caregivers who are responsible for the mainten-
ance and/or improvement of the QoL of these persons.
Two of the principal goals proposed by the World
Health Organization in their recent factsheet on dementia
to improve the lives of persons with dementia are to opti-
mise well-being and to identify and treat physical and psy-
chological problems [1]. The latter category contains many
factors that may be negatively associated with the QoL of a
person with dementia, including the presence of depres-
sion, behavioural problems, pain, comorbidity, living alone
and having needs that are unmet [3, 4]. The strength and
direction of these associations, however, vary considerably
between individuals [5]. One of the mentioned factors,
pain, can be treated. However, there is still a group of per-
sons with dementia that have undiagnosed and therefore
untreated pain. Untreated, it may be associated with
neuropsychological problems, e.g. behavioural problems
(agitation, aggression, psychosis) [6–9] and depression [9,
10]. On the other hand, in view of the large increase in
opioids and paracetamol prescription in the past years
[11–14], clinicians should be aware of side effects and
overtreatment with pain medication in this population.
The use of pain medication has been proven effective
on agitation [15, 16], depression and apathy [17], sleep
[18] and social interaction [19] in persons with demen-
tia. Two relatively small trials with a crossover design
were performed earlier to assess the effects of pain medi-
cation (paracetamol) in this target population. One in-
cluded 25 participants (mean age 85.9 years, 88% female)
living in LTCFs in which the authors concluded that
paracetamol improved social interaction [19]. The sec-
ond study included 39 participants (mean age 85.7, 87%
female, mean Global Deterioration Score 5.7) living in
LTCFs [20]. The researchers of this study found no signifi-
cant difference in discomfort between the placebo and
paracetamol groups. However, so far, no studies have inves-
tigated the effect of paracetamol on overall QoL of persons
with dementia. The question remains whether paracetamol
only has analgesic and antipyretic effects [21], or also other
(unknown) effects that may influence QoL in persons with
advanced dementia. Therefore, the present study aims to
investigate the effect of regularly scheduled administration
of paracetamol (acetaminophen) on QoL of persons with
dementia with low QoL, independent of having pain, living
in LTCFs. Furthermore, the effect of scheduled administra-
tion of paracetamol on discomfort, pain and neuropsychi-
atric symptoms will be assessed [22].
Methods
From January 2018 to June 2019, we performed a multi-
centre (block) randomised double-blind placebo-
controlled crossover trial for 13 weeks in LTCFs con-
nected to the University Network of the Care sector South
Holland (UNC-ZH) in the west of the Netherlands [22].
The UNC-ZH is a collaboration between the Leiden Uni-
versity Medical Center (LUMC) and large care organisa-
tions in the west of the Netherlands. Its goal is to initiate,
facilitate and perform care-related scientific research [23].
Participants and enrolment
This study aimed to include 95 LTCF residents aged ≥ 65
years, with (advanced) dementia stage 5, 6, or 7 according
to the Reisberg Global Deterioration Scale [24] and a
moderate to low QoL, total score ≤ 70 on QUALIDEM-6-
Domain total score (QUALIDEM-6D), independent of
having pain. This cut-off point was derived from the me-
dian of the QUALIDEM-6D scores found in a previous
Dutch study involving persons with dementia living in
LTCFs [25, 26].
Exclusion criteria were use of regular pain treatment
(residents who used paracetamol that was prescribed 'pro
re nata', or 'as needed' (PRN) were eligible only if the use
of paracetamol in the week previous to starting study
medication was ≤ 3 g/week with a maximum of 1 g/day), al-
lergies to the study medication (paracetamol or placebo),
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severe liver insufficiency or disease, use of > 4 units of alco-
hol/day, weight < 50 kg and/or concomitant use of fluclox-
acillin [27].
Intervention
Study medication was produced and provided by the phar-
macy of the LUMC. Participants received study medica-
tion in two periods of 6 weeks each with 1 week in
between as a wash-out period. One period consisted of
paracetamol, the other of placebo. In accordance with a
Dutch guideline for chronic use of paracetamol in older
persons, the dose of paracetamol in the first 4 weeks was
slightly higher (3 times/day 1000mg) than the last 2 weeks
of this period (2 times/day 1000mg and 1 time/day 500
mg) [28]. Placebo tablets were provided in the same
amount and resembled the paracetamol tablets in appear-
ance, taste and composition. The bitter taste was imitated
by adding a low dose of quinine (without therapeutic
activity) to the placebo substance. The study medication
was packaged in identical jars and administered to the
participants along with their other medication by nurses
and nursing assistants that were allowed to administer
medication, in the same way they were used taking their
medication. When, however, pain treatment was needed, a
single administration of paracetamol 1000mg was allowed
without consequences, but no more than 3 times/week.
When more pain treatment was needed, the participant
stopped study medication, but the measurements contin-
ued, following the intention-to-treat principle.
Randomisation, treatment allocation and blinding
Included participants were randomised in blocks of 4 by a
random number generator in the pharmacy of the LUMC.
Participants were randomised 1:1 into the paracetamol-
placebo (AB) or the placebo-paracetamol (BA) treatment
arm. Participants and their informal caregivers, re-
searchers, research nurse and professional caregivers in
the participating LTCFs were blinded to treatment alloca-
tion. Only the pharmacy of the LUMC knew which par-
ticipant was allocated to which treatment arm.
Outcome measures
All data concerning the primary and secondary outcomes
listed below were collected at baseline, 6 weeks, 7 weeks
and 13 weeks. QoL, discomfort and pain were observed by
the responsible nurse or nursing assistants, and neuro-
psychological symptoms were measured via interviews
with the nurse/nursing assistant by a research nurse.
Primary outcomes
Quality of life and discomfort
The short 18-item version of the QUALIDEM was used
to measure QoL. This version comprises six domains
(care relationship, positive affect, negative affect, restless
tense behaviour, social relationships and social isolation)
that are also applicable to persons with very severe de-
mentia [29, 30]. In order to calculate a total mean score
for QoL, the individual domain scores were re-calculated
to a percentage score by dividing the domain score by
its maximum achievable points multiplied by 100. Do-
main scores were then added up and divided by 6 to cal-
culate an overall mean score, the QUALIDEM-6D. Both
the domain scores and the overall mean score can range
from 0 (worst QoL possible) to 100 (best QoL possible).
These transformations have been applied successfully
multiple times in previous studies [12, 31–33].
The Discomfort Scale-Dementia of Alzheimer Type
(DS-DAT) was used to measure discomfort in persons
with advanced dementia [34]. It consists of nine items of
discomfort with a score ranging from 0 (no discomfort)
to 27 (worst possible discomfort).
Secondary outcomes
Pain
The nurse/nursing assistant observed pain in the partici-
pants during morning care using the Mobilization-
Observation-Behaviour-Intensity-Dementia-2 pain scale
(MOBID-2) [35, 36]. This observational instrument has
been proven reliable, valid and very responsive to change of
pain in persons with dementia [35, 37]. While moving
hands, arms and legs of the participant, turning the partici-
pant on both body sides on the bed and letting him/her sit
on the edge of the bed, the nurse/nursing assistant rated
pain intensity by observing facial expressions, vocalisations
and defending behaviour. Subsequently, the nurse/nursing
assistant rated pain intensity by observation based on pain
behaviour over the preceding week related to head/neck,
chest/lungs/heart, upper abdomen, legs/pelvis/lower abdo-
men and skin/wounds. A total pain score ranging from 0
(no pain) to 10 (worst pain possible) was assigned to these
observations. Scores ≥ 3 were seen as clinically relevant pain
[37].
Neuropsychiatric symptoms
Neuropsychiatric symptoms were measured with the
Neuropsychiatric Inventory—Nursing Home version (NPI-
NH) [38, 39]. This is an interview-based questionnaire
completed by the nurse/nursing assistant and the research
nurse, consisting of 13 items that are each scored for fre-
quency and severity. Total scores range from 0 (no behav-
ioural problems) to 144 (very severe behavioural problems).
Additional measurements at baseline
Demographic data were collected at the start of the
study by the nursing staff and the treating elderly care
physicians. The severity of dementia was measured with
the Reisberg Global Deterioration Scale (GDS), which
reflects the stage of progression of the disease from 1
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(no cognitive decline) to 7 (very severe cognitive decline)
[24]. Comorbidity was assessed using the Functional Co-
morbidity Index, a list of 18 comorbid diseases that are
associated with physical function [40].
Compliance
The participants’ compliance to study medication was
tracked by counting residual study medication after each
finished study period. A leftover tablet count of > 10% (> 24
missed tablets) per period was considered non-compliant.
Also, the medication intake was registered on a medication
registration form by the nurse/nursing assistant each time
the (study) medication was administered. When partici-
pants refused study medication repeatedly, the nurse/nurs-
ing assistant informed the researchers and the study
medication was discontinued on the medication adminis-
tration form. The same applied to participants who had to
stop because of starting (other) pain medication.
Sample size calculation
A sample size of 70 participants was calculated based on
the detection of an inter-individual difference of 10% on
the primary outcome measure QUALIDEM, with 80%
power, and alpha 0.05. To account for an estimated
dropout of 35% (mortality, loss to follow-up, (other) pain
medication needed, etc.), enrolment of 95 participants
was planned.
Statistical analysis
At baseline, the characteristics and outcome measures in
the two different treatment arms were compared using
unpaired t tests for normally distributed numerical data,
one-way ANOVA tests for non-normally distributed
data and chi-squared tests for categorical data.
The decision which statistical tests to use was based on
whether the main outcome measure QUALIDEM showed
an order and/or period effect. The calculation of these ef-
fects was extensively described in the protocol article of
this study [22]. If no significant order and/or period effect
was found, the two treatment groups, i.e. placebo and
paracetamol, would be compared using paired t tests for
normally distributed numerical data, Wilcoxon signed-
rank tests for non-normally distributed data and chi-
squared tests for categorical data. In case of any order
and/or period effect, repeated linear mixed models were
used with adjustment for order and/or period effects.
Patient and public involvement
The topic of our study was identified by the quality of life
feedback group, in which care professionals of LTCFs par-
ticipate. The members of the UNC-ZH (care organisations),
combined with the client panel of older people from the
LUMC and the QoL feedback group, felt that they needed
feasible and evidence-based interventions that could help
achieve optimal QoL in persons with (advanced) dementia.
Therefore, they provided input to the researchers and the
UNC-ZH to develop this study. The study was subse-
quently designed and performed in co-creation with these
three groups.
Results
Enrolment and study flow
A total of 731 patient information letters were sent to
legal representatives of eligible participants. Of these
legal representatives, 228 consented to screening. Nine
persons in this screening group died before enrolment/
randomisation, and 21 persons were not screened be-
cause the planned number of 95 participants was
reached. One hundred ninety-eight eligible participants
were eventually screened for inclusion and exclusion cri-
teria. The main reasons for exclusion were a QUALI-
DEM > 70 (62 persons), using pain medication and/or
medication interacting with study medication (21 per-
sons), weight < 50 kg (18 persons) and a GDS score
below 5 (16 persons). All reasons for exclusion can be
found in Fig. 1. Finally, 95 LTCF residents with ad-
vanced dementia across 17 LTCFs (9 care organisations)
in the west of the Netherlands were enrolled in this
study: 47 in the paracetamol-placebo (AB) arm and 48
in the placebo-paracetamol (BA) arm.
During the study, 9 participants died (not study-
related), of whom 8 in the first study period.
Baseline characteristics of participants
The mean age of the participants was 83.9 years (SD
7.6), 57.9% were female, the majority had a GDS score of
6 (70.5%) and the mean number of comorbidities ac-
cording to the FCI in the total group was 2.7 (SD 2.0).
These participant characteristics did not differ at base-
line across both treatment arms (Table 1).
Order and period effects
Comparing the treatment effects of paracetamol on the
QUALIDEM of both groups in both periods, i.e. the ef-
fect of paracetamol minus the effect of placebo, revealed
a significant difference in mean differences of the QUA-
LIDEM total scores between the two treatment arms
(4.5 in the AB arm and -4.8 in the BA arm; p = 0.008),




At baseline, the groups in the two treatment arms did not
differ on QUALIDEM-6D total scores (AB arm 58.1 [SD
13.1] vs. BA arm 57.0 [SD 13.8]; p = 0.701) and the six
QUALIDEM domain scores (Table 1). The QUALIDEM-
Dam et al. BMC Medicine          (2020) 18:407 Page 4 of 10
6D scores of each treatment arm during the study are
shown in Fig. 2.
A strong period effect, i.e. the mean changes in both
periods in the total group of participants were signifi-
cantly different, was found for the QUALIDEM-6D total
score (+3.8 in period 1 vs. -1.0 in period 2; p = 0.004),
and the subdomain negative affect (6.7 in period 1 vs.
-1.2 in period 2; p = 0.005).
Application of repeated linear mixed models subse-
quently showed no differences in the QUALIDEM-6D
total scores and domain scores in favour of either para-
cetamol or placebo (Table 2).
Discomfort
The groups in the two treatment arms did not differ on
DS-DAT total scores at baseline (AB arm 8.4 [SD 4.9]
vs. BA arm 8.3 [SD 6.0]; p = 0.970). No difference was
found in the treatment effects of paracetamol and pla-
cebo (paracetamol -0.04 [95% CI -1.3–1.3] vs. placebo
0.6 [95% CI -0.7–1.9]) (Table 2).
Secondary outcomes
Pain
Mean MOBID-2 pain scores at baseline were similar in
both treatment arms (AB arm 2.0 [SD 2.4] vs. BA arm
2.3 [SD 3.0]; p = 0.531) (Table 1). No difference in
treatment effect on pain was found between both treat-
ments (paracetamol 0.0 [95% CI -0.5–0.5], placebo -0.2
[95% CI -0.7–0.3]) (Table 2).
Neuropsychiatric symptoms
At the start of the study, there was no significant differ-
ence in NPI-NH total mean scores between the groups in
the two treatment arms (AB arm 32.6 [SD 21.0] and BA
arm 33.5 [SD 18.9]; p = 0.822) and the three subdomain
scores (psychosis 3.7 [SD 5.8] vs. 3.7 [SD 4.6], p = 0.974;
agitation 10.6 [SD 8.6] vs. 11.9 [SD 10.0], p = 0.512;
affective symptoms 5.9 [SD 6.2] vs. 4.8 [SD 5.7], p = 0.396)
(Table 1). No difference in treatment effect between para-
cetamol and placebo was found for the NPI-NH total
mean score and the three subdomain scores (Table 2).
Compliance
Five participants quit study medication in the first
period and 11 in the second study period. Reasons for
quitting study medication were repeated refusal of study
tablets (7 participants) and being in need of (other) pain
medication (9 participants). Two participants from the
latter group performed much better in the first period,
and the nurses detected a clear deterioration in the sec-
ond period. This caused them to contact the researchers
to quit study medication and to continue paracetamol
Fig. 1 Flowchart of the Q-PID trial
* Some overlap exists in the number of stated reasons for exclusion, because some persons met more than 1 exclusion criterium
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(although unsure which treatment arm the participant
was in, the difference between the two periods was
evident). After the study ended and after deblinding,
these participants indeed turned out to be part of the
AB treatment arm (first paracetamol, then placebo). At
least two other patients did not stop study medication,
but the nurses again saw a clear difference and when
paracetamol was continued after the study ended, the
participants performed better and were more relaxed.
In the first study period, the median compliance was
92.0% (IQR 80.7–100.0), taking into account participants
who died and who stopped study medication during this
period. Data for 14 participants on the number of re-
sidual tablets at the end of the first period was missing,
due to the absence of the study medication jars on the
LTCF units after the study period ended. In the second
study period, the median compliance was 84.0% (IQR
67.5–98.1), taking into account participants who died
and who stopped study medication during this and pre-
vious study period. Compliance data for 18 participants
was missing for the same reason as in period 1. The
medication administration records showed better com-
pliance than the residual tablet counting, indicating an
imbalance between recording the study medication as
‘given’ and actually giving it.
Discussion
The present study shows that paracetamol, compared to
placebo, did not improve QoL, discomfort, pain and
neuropsychiatric symptoms in persons with advanced
dementia. It is important to take a closer look at the ap-
propriateness of prescribing pain medication in these
vulnerable persons. Also, doctors need to be aware that
medication for sleep and neuropsychiatric symptoms has
side effects and that (undertreated) pain may be the
cause of sleep problems and/or neuropsychiatric symp-
toms, as has been described by others [41].
Several strengths and limitations can be mentioned.
First, to our knowledge, this is the largest crossover study
with persons with dementia performed in LTCFs. The
crossover design is an efficient study design that requires
a substantially smaller sample size than trials with parallel
Table 1 Baseline characteristics and measurements of the total group, stratified by randomisation group
Paracetamol-placebo, N = 47 Placebo-paracetamol, N = 48
Mean age (SD) in years 83.9 (7.5) 83.9 (7.7)
Female (%) 27 (57.4) 28 (58.3)
GDS score 7 (%) 10 (21.3) 10 (20.8)
FCI, 0–18 (SD) 2.9 (1.9) 2.5 (2.1)
QUALIDEM-6D
Total score 0–100 (SD) 58.1 (13.1) 57.0 (13.8)
A—Care relationship 0–100 (SD) 58.0 (22.3) 56.9 (23.0)
B—Positive affect 0–100 (SD) 69.6 (18.6) 68.4 (19.7)
C—Negative affect 0–100 (SD) 63.8 (28.0) 64.2 (25.0)
D—Restless tense behaviour 0–100 (SD) 37.9 (25.5) 39.8 (28.6)
F—Social relationships 0–100 (SD) 64.0 (21.2) 58.8 (20.9)
G—Social isolation 0–100 (SD) 55.1 (20.8) 53.7 (23.7)
DS-DAT, 0–27 (SD) 8.4 (4.9) 8.3 (6.0)
Pain (MOBID-2 ≥ 3) (%) 15 (33.3)* 15 (31.3)
MOBID-2 overall pain intensity, 0–10 (SD) 2.0 (2.4) 2.3 (3.0)
NPI-NH
Total score, 0–144 (SD) 32.6 (21.0) 33.5 (18.9)
Psychosis 0–24 (SD) 3.7 (5.8) 3.7 (4.6)
Agitation 0–48 (SD) 10.7 (8.6) 11.9 (9.7)
Affective symptoms 0–24 (SD) 5.9 (6.2) 4.8 (5.7)
No psychotropic use† (%) 29 (61.7)** 19 (39.6)**
SD standard deviation, GDS Global Deterioration Scale, FCI Functional Comorbidity Index, QUALIDEM-6D dementia-specific QoL measurement instrument, 6 domain
version, DS-DAT Discomfort Scale-Dementia of Alzheimer Type, MOBID-2 Mobilization-Observation-Behaviour-Intensity-Dementia-2 pain scale, NPI-NH
Neuropsychiatric Inventory—Nursing Home version
*Missing, 2
**p value 0.031 (Pearson chi-square)
†Psychotropics: antipsychotics, antidepressants, anxiolytics, hypnotics and anti-dementia drugs
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groups [42, 43], causing less variance between measure-
ments. Consequently, up to four times less participants
are needed to reach the same power as a parallel group
study. In view of the target group, this was an important
consideration in choosing the design for this study. More-
over, the crossover design is very suitable when a wash-
out period longer than five times the halftime of the inter-
vention can be fitted into the study design, so that no
carry-over effects are expected after stopping or changing
intervention. Also, confounding is minimised since the
participants are their own controls and baseline character-
istics will therefore be equal.
Prior to the study, we were aware, due to previous expe-
riences in research in this field, that only approximately
10% of all persons with dementia living in the participat-
ing LTCFs would be eligible to participate. Therefore, a
lot of effort was needed and made in the present study to
achieve the goal of enrolling 95 participants, which
succeeded within the planned time frame. Furthermore,
the study was performed within the care organisations
that are member of the UNC-ZH, which assures a good
research infrastructure.
Obviously, research in persons with advanced dementia
living in LTCFs is complex and does not resemble research
in a preconceived environment. One of the prerequisites to
perform a crossover study is that the disease that will be
studied is chronic and has a stable course. As we saw in
our results, the entire group of participants performed
worse in the second study period, irrespective of which
treatment arm they were in. Therefore, we used mixed ef-
fects models accounting for this period effect, rather than
simply comparing the treatment groups crosswise. It may
be possible that the dementia (and other comorbidities) de-
teriorated during the course of the study, which may have
caused worse outcomes in the second period. We did not
record the course of progression of the dementia and co-
morbidities during follow-up. It is also possible that the
workload accompanying the present study caused the
nurses/nursing assistants to be less motivated in the sec-
ond period, contributing to the period effects found for the
QUALIDEM and the NPI-NH.
Second, the time frames in which questionnaires needed
to be completed at each time point were tight, so it was
not always feasible to have the same nurse/nursing assist-
ant complete the questionnaires at all time points for the
same participant. Although we used questionnaires that
are thoroughly validated, there is always a component of
subjectivity, in which the connection between the person
with dementia and the nurse/nursing assistant is import-
ant for how the questionnaires are completed.
Third to mention is the compliance of the study medi-
cation. The number of participants that quit study medi-
cation as reported by nursing staff was within our a
priori estimated ‘quit rate’ (35% of 95 participants), but
when counting the remaining tablets after each period,
more participants appeared to have not received their
study medication according to our definition of compli-
ance (missed < 10% of tablets). Nevertheless, the median
Fig. 2 Mean QUALIDEM domain scores and mean QUALIDEM-6D total scores in the two treatment groups during the Q-PID study
QUALIDEM, questionnaire to measure QoL in persons with dementia, range 0 (worst QoL) to 100 (best QoL); QUALIDEM-6D, 6-domain total score
of the QUALIDEM questionnaire, range 0 (worst overall QoL) to 100 (best overall QoL); paracetamol-placebo, baseline to 6 weeks paracetamol,
7 to 13 weeks placebo; placebo-paracetamol, baseline to 6 weeks placebo, 7 to 13 weeks paracetamol
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compliance in both periods was still 92.0% and 84.0%.
The study medication could not be provided in the same
unit dose packages as the other medication, due to logis-
tical problems between the separate preferred pharma-
cies in 17 nursing homes, and the additional costs
associated with the organisation of this method/finances.
This may have contributed for a large part to the non-
corresponding compliance numbers of counting residual
tablets after each period and recorded numbers as signed
on the medication administration forms.
Lastly, planning a sufficiently long enough wash-out
period requires extensive knowledge on the working
dynamics of the treatment. Although we accounted for
the half-life of paracetamol (on average 2.7 h), partici-
pants may have experienced a beneficial psychological
effect of paracetamol that lasted throughout the second
period (hence the period effect that was found). More-
over, paracetamol may not be strong enough to treat all
types of pain in persons with dementia, which may ex-
plain why no differences were found between paraceta-
mol and placebo treatment in the complete group of
participants.
Compared with the distribution of males/females
found in earlier research among persons with advanced
Table 2 Treatment effects of paracetamol and placebo on quality of life, discomfort, pain and neuropsychiatric symptoms. N = 95
(baseline), N = 86 (end of study)
Intervention Mean difference 95% CI p value
QUALIDEM-6D†
Total score Paracetamol 1.3 -1.0–3.5 0.876
Placebo 1.5 -0.7–3.8
A—Care relationship Paracetamol 2.9 -1.0–6.9 0.128
Placebo -1.4 -5.3–2.5
B—Positive affect Paracetamol 0.3 -3.7–4.3 0.872
Placebo 0.7 -3.2–4.7
C—Negative affect Paracetamol 2.6 -1.4–6.6 0.919
Placebo 2.9 -1.0–6.9
D—Restless tense behaviour Paracetamol 2.1 -3.1–7.3 0.955
Placebo 2.3 -2.8–7.5
F—Social relationships Paracetamol -1.1 -5.3–3.1 0.192
Placebo 2.9 -1.3–7.0
G—Social isolation Paracetamol 0.9 -3.6–5.3 0.803
Placebo 0.1 -4.3–4.5
DS-DAT‡ Paracetamol -0.1 -1.4–1.2 0.478
Placebo 0.6 -0.7–1.8
MOBID-2* Paracetamol 0.0 -0.5–0.5 0.605
Placebo -0.2 -0.7–0.3
NPI-NH††
Total score Paracetamol 1.5 -2.3–5.4 0.187
Placebo -2.1 -6.0–1.7
Psychosis Paracetamol -0.3 -1.4–0.8 0.935
Placebo -0.3 -1.4–0.8
Agitation Paracetamol 1.2 -0.7–3.0 0.077
Placebo -1.2 -3.0–0.7
Affective symptoms Paracetamol -0.3 -1.5–0.9 0.516
Placebo 0.2 -0.9–1.4
Repeated linear mixed models, adjusted for order and period effects, and psychotropic use
CI confidence interval, QUALIDEM-6D dementia-specific QoL measurement instrument, 6 domain version, DS-DAT Discomfort Scale-Dementia of Alzheimer Type,
MOBID-2 Mobilization-Observation-Behaviour-Intensity-Dementia-2 pain scale, NPI-NH Neuropsychiatric Inventory-Nursing Home version
*Higher score means more pain
†Higher score means better QoL
‡Higher score means more discomfort
††Higher score means more neuropsychiatric symptoms
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dementia living in LTCF (about 72% or more female [4,
11, 19, 44]), our study had relatively fewer women
(57.9%). An explanation for this could be that we in-
cluded persons based on their QoL, and apparently, rela-
tively more males had a low QoL. Also, the mean NPI
total score in our research population was higher than
that found in other studies in persons with advanced de-
mentia living in LTCF (33 in our study vs. 12–16 in
other studies [4, 44]). QoL may be affected to a consid-
erable degree by neuropsychiatric symptoms, which is
probably what we saw in our research population, as we
selected our participants on low QoL and found rela-
tively more neuropsychiatric symptoms.
The present study aimed to increase QOL in persons
with dementia that were or were not in pain with pain
treatment. No positive effects of regularly scheduled
administration of paracetamol on QoL, discomfort, pain
and neuropsychiatric symptoms in persons with advanced
dementia were found, compared to placebo. However,
there were individual cases that clearly derived benefit
from paracetamol during and after the study. This could
have important implications for future prescriptions of
pain medication in persons with advanced dementia, and
it raises questions on the statistical significance vs. the
clinical relevance of the results. We showed that perform-
ing research in this vulnerable group living in LTCFs is a
challenge, especially in finding the right balanced study
design that accounts for this population, of which the
characteristics (comorbidities and illness/death) can
change quickly over a short amount of time. In addition,
more research should be performed to find out which per-
sons with dementia benefit from pain treatment, and
which do not. Following this study, more attention should
be paid to the compliance of medication that is adminis-
tered outside a ‘unit dose package’ by a nurse/nursing as-
sistant. Clinicians should be aware that good assessment
and monitoring, and a multidomain approach instead of
only prescribing pain medication, is vital for improving
QoL in this vulnerable group.
Conclusions
In this study, paracetamol did not show positive effects
on QoL, discomfort, pain and neuropsychiatric symp-
toms in persons with advanced dementia with low QoL.
It is important to find out more specifically which per-
sons with advanced dementia could individually benefit
from pain treatment with paracetamol.
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